ATE192732T1 - Caroboxy- oder tetrazolengruppen enthaltende dialkylether - Google Patents

Caroboxy- oder tetrazolengruppen enthaltende dialkylether

Info

Publication number
ATE192732T1
ATE192732T1 AT96903794T AT96903794T ATE192732T1 AT E192732 T1 ATE192732 T1 AT E192732T1 AT 96903794 T AT96903794 T AT 96903794T AT 96903794 T AT96903794 T AT 96903794T AT E192732 T1 ATE192732 T1 AT E192732T1
Authority
AT
Austria
Prior art keywords
tetrazolene
caroboxy
dialkylethers
groups
noninsulin
Prior art date
Application number
AT96903794T
Other languages
English (en)
Inventor
Charles Larry Bisgaier
Paul Leroy Creger
Alan Robert Saltiel
Sherrie Rae Tafuri
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE192732T1 publication Critical patent/ATE192732T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/305—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/28—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
    • C07C47/37—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/305—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups
    • C07C59/315—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups
    • C07C59/353—Saturated compounds containing more than one carboxyl group containing keto groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Dental Preparations (AREA)
AT96903794T 1995-03-24 1996-02-05 Caroboxy- oder tetrazolengruppen enthaltende dialkylether ATE192732T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/409,780 US5648387A (en) 1995-03-24 1995-03-24 Carboxyalkylethers, formulations, and treatment of vascular diseases
PCT/US1996/001639 WO1996030328A1 (en) 1995-03-24 1996-02-05 Terminal carboxy or tetrazole groups containing dialkyl ethers

Publications (1)

Publication Number Publication Date
ATE192732T1 true ATE192732T1 (de) 2000-05-15

Family

ID=23621941

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96903794T ATE192732T1 (de) 1995-03-24 1996-02-05 Caroboxy- oder tetrazolengruppen enthaltende dialkylether

Country Status (27)

Country Link
US (4) US5648387A (de)
EP (1) EP0820428B1 (de)
JP (1) JP3885115B2 (de)
KR (1) KR100408612B1 (de)
CN (1) CN1100747C (de)
AT (1) ATE192732T1 (de)
AU (1) AU692359B2 (de)
BG (1) BG63534B1 (de)
CA (1) CA2215233C (de)
CZ (1) CZ289556B6 (de)
DE (1) DE69608268T2 (de)
DK (1) DK0820428T3 (de)
EE (1) EE03520B1 (de)
ES (1) ES2148733T3 (de)
FI (1) FI973713A (de)
GR (1) GR3034109T3 (de)
HK (1) HK1009438A1 (de)
HU (1) HUP9801825A3 (de)
NO (1) NO307878B1 (de)
NZ (1) NZ302170A (de)
PL (1) PL181673B1 (de)
PT (1) PT820428E (de)
RU (1) RU2191772C2 (de)
SK (1) SK282897B6 (de)
UA (1) UA46020C2 (de)
WO (1) WO1996030328A1 (de)
ZA (1) ZA962275B (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119971A (en) * 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus
US6861555B2 (en) * 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
KR20010033017A (ko) * 1997-12-12 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 과지질혈증 치료제인 스타틴-ＬＰ(ａ) 억제제의 병용 제제
SI1045691T1 (en) * 1997-12-12 2005-04-30 Warner-Lambert Company Llc Statin-carboxyalkylether combinations
US20030105154A1 (en) * 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
ATE320803T1 (de) * 1998-01-28 2006-04-15 Warner Lambert Co Verfahren zur behandlung von alzheimerschen krankheit
HUP0103648A3 (en) * 1998-09-30 2003-10-28 Warner Lambert Co Method for preventing or delaying catheter-based revascularization
EP1849760A1 (de) * 1999-04-01 2007-10-31 Esperion Therapeutics Inc. Ether-Verbindungen, Zusammensetzungen und ihre Verwendung
CN1329359C (zh) 1999-04-01 2007-08-01 埃斯佩里安医疗公司 醚化合物,及其组合物和用途
ATE431326T1 (de) 2000-01-25 2009-05-15 Warner Lambert Co Calcium-dicarboxylatether, verfahren zu deren herstellung
US20040092574A1 (en) * 2000-02-07 2004-05-13 Bisgaier Charles Larry Statin-Lp(a) inhibitor combinations
KR20020091245A (ko) * 2000-04-26 2002-12-05 워너-램버트 캄파니 항고혈압제 및 용도
CA2414783A1 (en) * 2000-07-14 2002-01-24 Warner-Lambert Company Treatment of eating disorders using carboxyalkylethers
CN1479721A (zh) * 2000-10-11 2004-03-03 ͨ��ҽ�ƹ�˾ 用于胆固醇治疗和相关应用的亚砜和双亚砜化合物和组合物
US7304093B2 (en) * 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
JP2004529069A (ja) * 2000-10-11 2004-09-24 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理用のエーテル化合物及び組成物ならびに関連する使用
BR0114619A (pt) 2000-10-11 2005-12-13 Esperion Therapeutics Inc Composto, composição farmacêutica, métodos para tratar ou prevenir uma doença cardiovascular, uma dislipidemia, uma dislipoproteinemia, um distúrbio do metabolismo da glicose, trombótico e associado com o receptor ativado do proliferador de peroxissoma, a doença de alzheimer, a sìndrome x ou sìndrome metabólica, a septicemia, a obesidade, pancreatite, a hipertensão, doença renal, câncer, a inflamação e a impotência, em um paciente e para reduzir o teor de gordura da carne em animal de criação e de colesterol de ovos de aves domésticas
AU1313602A (en) 2000-10-11 2002-04-22 Esperion Therapeutics Inc Ketone compounds and compositions for cholesterol management and related uses
US20040122091A1 (en) * 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20030225123A1 (en) * 2001-03-22 2003-12-04 Auerbach Bruce Jeffrey Antihypertensive agents and use
US20040072903A1 (en) * 2001-05-08 2004-04-15 Auerbach Bruce Jeffrey Carboxyalkylether-acat inhibitors combinations
US20040192771A1 (en) * 2001-10-11 2004-09-30 Dasseux Jean-Louis Henri Ether compounds and compositions for cholesterol management and related uses
US20040204502A1 (en) * 2001-10-11 2004-10-14 Dasseux Jean-Louis Henri Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20050020694A1 (en) * 2001-10-11 2005-01-27 Dasseux Jean-Louis Henri Sulfide and disulfide compounds and compositions for cholesterol management and related uses
EP1495034A2 (de) * 2002-04-10 2005-01-12 Esperion Therapeutics, Inc. Acyl-coenzym-a nachahmer aus pantolacton und pantothensäurederivaten, deren zusammensetzungen und verfahren zur cholesterinkontrolle sowie verwandte verwendungen davon
MXPA05001254A (es) * 2002-08-22 2005-06-08 Warner Lambert Co Procedimiento para el tratamiento de la osteoartritis.
US20040048910A1 (en) * 2002-08-22 2004-03-11 Bove Susan Elizabeth Method of treating osteoarthritis
US20040110803A1 (en) * 2002-09-13 2004-06-10 Hossein Dovlatabadi Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels
CA2505915A1 (en) * 2002-11-15 2004-06-03 Warner-Lambert Company Llc Method of lowering crp and reducing systemic inflammation
PT2404890T (pt) * 2003-01-23 2017-10-23 Esperion Therapeutics Inc Compostos de hidroxilo e composições para gestão do colesterol e utilizações relacionadas
US20040229954A1 (en) * 2003-05-16 2004-11-18 Macdougall Diane Elaine Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt
WO2005002557A1 (en) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
CA2543596A1 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
US20050192347A1 (en) * 2003-12-23 2005-09-01 Dasseux Jean-Louis H. Urea and thiourea compounds and compositions for cholesterol management and related uses
WO2005068410A1 (en) * 2003-12-24 2005-07-28 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
EP1701931B1 (de) 2003-12-24 2018-10-10 Esperion Therapeutics, Inc. Ketonverbindungen und zusammensetzungen zur behandlung von cholesterol und deren verwendung
WO2005123686A1 (en) * 2004-06-09 2005-12-29 Avanir Pharmaceuticals Heterocyclic derivatives for treatment of hyperlipidemia and related diseases
TW200603794A (en) * 2004-06-09 2006-02-01 Avanir Pharmaceuticals Small molecules for treatment of hypercholesterolemia and related diseases
AU2005255013A1 (en) * 2004-06-09 2005-12-29 Avanir Pharmaceuticals Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
WO2006045010A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
EP2314295B1 (de) * 2005-07-29 2015-01-28 Resverlogix, Inc Arzneimittel zur Prävention und Behandlung komplexer Erkrankungen und deren Freisetzung mittels einsetzbarer Medizinprodukte
US7777071B2 (en) * 2006-08-11 2010-08-17 Ssv Therapeutics, Inc. Production of carnitine conjugate intermediates
MX2009008099A (es) * 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
EP2431043A1 (de) 2007-05-23 2012-03-21 Amcol International Corporation Mit Cholesterin interagierende Phyllosilikate zur Unterdrückung der gastrointestinalen Cholesterinabsorption
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
KR101629356B1 (ko) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 퀴나졸리논 유도체의 제조방법
CA2747417C (en) 2009-01-08 2017-01-03 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
BRPI1014956B8 (pt) 2009-04-22 2021-05-25 Resverlogix Corp agentes anti-inflamatórios
WO2011027257A2 (en) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
RU2013118021A (ru) 2010-09-20 2014-10-27 Кареус Терапьютикс, Са Способы и композиции для лечения сахарного диабета и дислипидемии
MX337179B (es) 2010-10-18 2016-02-15 Cerenis Therapeutics Holding Sa Compuestos, composiciones y metodos utiles para la movilizacion de colesterol.
PL2658536T3 (pl) 2010-12-27 2017-04-28 Gemphire Therapeutics Inc. Gemcabene i pochodne do leczenia pancreatitis
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
JP5992049B2 (ja) 2011-11-01 2016-09-14 レスバーロジックス コーポレイション 置換されたキナゾリノンのための経口速放性製剤
US10028926B2 (en) 2012-01-06 2018-07-24 Gemphire Therapeutics Inc. Methods of reducing risk of cardiovascular disease
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
SG11201609084QA (en) 2014-05-02 2016-11-29 Cerenis Therapeutics Holding Sa Hdl therapy markers
CN111704543A (zh) 2014-11-14 2020-09-25 燿石治疗公司 用于制备α,ω-二羧酸封端的二烷醚的方法和中间体
JP6903585B2 (ja) 2015-03-13 2021-07-14 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法
JP6940411B2 (ja) 2015-03-13 2021-09-29 エスペリオン・セラピューティクス・インコーポレイテッドＥｓｐｅｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
RU2018120599A (ru) * 2015-11-06 2019-12-09 Джемфир Терапьютикс, Инк. Лечение смешанной дислипидемии
WO2018165120A1 (en) * 2017-03-06 2018-09-13 Gemphire Therapeutics Inc. Effect of carboxyalkylethers on obesity symptoms and lipodystropy
TW201902471A (zh) * 2017-04-18 2019-01-16 美商珍費爾醫療公司 賈卡賓尼（ｇｅｍｃａｂｅｎｅ）、其醫藥上可接受之鹽、彼等之組成物及使用彼等之方法
CN112437765A (zh) 2019-06-21 2021-03-02 艾斯柏伦治疗公司 贝派地酸的盐形式及其使用方法
EP4003314B1 (de) 2019-07-26 2024-07-10 Espervita Therapeutics, Inc. Funktionalisierte langkettige kohlenwasserstoffmono- und -dicarbonsäuren zur vorbeugung oder behandlung von krankheiten
EP4171541A1 (de) 2020-06-24 2023-05-03 NeuroBo Pharmaceuticals, Inc. Gemcaben zur behandlung von zytokinstürmen und virusinduzierten entzündungen
TW202237073A (zh) 2021-01-25 2022-10-01 美商艾斯佩維他治療學公司 官能化長鏈烴單羧酸及二羧酸及其衍生物以及其於預防或治療疾病之用途
TW202245804A (zh) 2021-01-25 2022-12-01 美商艾斯佩維他治療學公司 官能化長鏈烴單羧酸及二羧酸及其衍生物以及其於預防或治療疾病之用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2466419A (en) * 1948-02-07 1949-04-05 Eastman Kodak Co beta, beta'-oxydipropionic acids and process of preparation
US3320079A (en) * 1960-07-11 1967-05-16 Eastman Kodak Co Ether-acid polyester composition
US3431298A (en) * 1965-01-05 1969-03-04 Asahi Chemical Ind Process for the preparation of oxadicarboxylic acids
US3674836A (en) * 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US3930024A (en) * 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
BE755997A (fr) * 1969-09-11 1971-03-10 Bp Chem Int Ltd Production d'acides dicarboxyliques
US3742068A (en) * 1970-04-17 1973-06-26 G Moersch Ethers of 2,2,9,9-tetramethyl-1,10-decanediol
IT1168389B (it) * 1981-05-06 1987-05-20 Alfa Farmaceutici Spa Derivati di alcandioli con attivita' ipolipidemizzante,metodi per la loro preparazione e composizioni farmaceutiche che li contengono
DE3423166A1 (de) * 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
IL84953A (en) * 1987-12-28 1992-01-15 Bromine Compounds Ltd 3,3'-oxy-bis((2,2'-di(bromomethyl)propanoic acid)derivatives,processes for their preparation and their use as flame retardant agents
DE3814498A1 (de) * 1988-04-29 1989-11-09 Basf Ag Verfahren zur herstellung von hydroxicarbonsaeureestern
US5395917A (en) * 1993-05-21 1995-03-07 E. I. Du Pont De Nemours And Company Polyimides from 4-(3-aminophenoxy)benzoic acid

Also Published As

Publication number Publication date
WO1996030328A1 (en) 1996-10-03
CZ289556B6 (cs) 2002-02-13
ES2148733T3 (es) 2000-10-16
PT820428E (pt) 2000-09-29
HUP9801825A2 (hu) 1998-12-28
FI973713A0 (fi) 1997-09-17
NO974397D0 (no) 1997-09-23
RU2191772C2 (ru) 2002-10-27
MX9707198A (es) 1997-11-29
KR19980703233A (ko) 1998-10-15
EP0820428B1 (de) 2000-05-10
HK1009438A1 (en) 1999-09-10
CZ292297A3 (cs) 1998-10-14
CA2215233C (en) 2006-07-11
DK0820428T3 (da) 2000-08-28
US5783600A (en) 1998-07-21
SK128697A3 (en) 1999-02-11
UA46020C2 (uk) 2002-05-15
BG63534B1 (bg) 2002-04-30
PL181673B1 (pl) 2001-08-31
AU692359B2 (en) 1998-06-04
NO974397L (no) 1997-11-20
NZ302170A (en) 1999-04-29
FI973713A (fi) 1997-09-24
GR3034109T3 (en) 2000-11-30
SK282897B6 (sk) 2003-01-09
KR100408612B1 (ko) 2004-03-26
AU4776896A (en) 1996-10-16
EE9700375A (et) 1998-06-15
DE69608268D1 (de) 2000-06-15
US5756544A (en) 1998-05-26
NO307878B1 (no) 2000-06-13
HUP9801825A3 (en) 2001-01-29
JP3885115B2 (ja) 2007-02-21
EE03520B1 (et) 2001-10-15
ZA962275B (en) 1996-11-27
US5750569A (en) 1998-05-12
BG101993A (en) 1998-05-29
EP0820428A1 (de) 1998-01-28
DE69608268T2 (de) 2000-11-09
JPH11502532A (ja) 1999-03-02
CA2215233A1 (en) 1996-10-03
CN1100747C (zh) 2003-02-05
US5648387A (en) 1997-07-15
PL322407A1 (en) 1998-01-19
CN1182415A (zh) 1998-05-20

Similar Documents

Publication Publication Date Title
ATE192732T1 (de) Caroboxy- oder tetrazolengruppen enthaltende dialkylether
DE69113405D1 (de) Chirurgischer Klebstoff.
FI954888A (fi) Selluloosaa sitova alue
DE69301036D1 (de) Hochdruckturbinenkomponenten mit Pressitz
DE59106678D1 (de) Optisch nichtlineare Polymerschichten.
FR2694497B1 (fr) Desodorisant de table.
DE59101652D1 (de) Operationsleuchte.
FI923099A0 (fi) Biomassa foer att producera virus/ virusantigen.
ITTO920629A1 (it) Cartoncino laminato leggero.
DE69114127D1 (de) Lichtaktivierter wandler.
FI914426A (fi) Foerfarande foer framstaellning av 1-( (2s)-3-merkaptometyl-1-oxopropyl)l-prolin.
NO901651D0 (no) Anordning ved tank.
FI86270B (fi) Foerfarande foer framstaellning av en relief.
NO912779D0 (no) Takfeste for livline.
FR2711710B1 (fr) Eléments funéraires légers.
IT9009009A1 (it) Stufa luminosa artistica.
ES1012887Y (es) Placa-soporte de sobremesa para anotaciones telefonicas.
ITME950020A0 (it) Impianto trattamento r.s.u.
NO900579L (no) Operasjonsbord.
NO902987L (no) Fremgangsmaate ved alkylering.
ES1033653Y (es) Cuadro perfeccionado.
NO905473D0 (no) Behandlingsanlegg for alpechin.
ITRM910239U1 (it) Protesi fonetica per laringectomizzati.
FI905433A (fi) Tank foer ackumulering av gas.
NO903425D0 (no) Anordning ved trinse.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee